Mannose 6-phosphate-modified N-glycans are the determinant for intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome. The enzyme responsible for the initial step in the synthesis of mannose 6-phosphate is UDP-N-acetylglucosamine:lysosomalenzyme-N-acetylglucosmine-1-phosphotransferase(GlcNAc-phosphotransferase). GlcNAc-phosphotransferase is a multisubunit enzyme with an ␣ 2 ␤ 2 ␥ 2 arrangement that requires a detergent for solubilization. Recent cloning of cDNAs and genes encoding these subunits revealed that the ␣-and ␤-subunits are encoded by a single gene as a precursor, whereas the ␥-subunit is encoded by a second gene. The hydropathy plots of the deduced amino acid sequences suggested that the ␣-and ␤-subunits but not the ␥-subunit contain transmembrane domains. Access to these cDNAs allowed us to express a soluble form of human recombinant GlcNAc-phosphotransferase by removing the putative transmembrane and cytoplasmic domains from the ␣-and ␤-subunits. Because this modification prevented precursor processing to mature ␣-and ␤-subunits, the native cleavage sequence was replaced by a cleavage site for furin. When the modified ␣/␤-subunits (␣/␤-subunits) precursor and wild type ␥-subunit cDNAs were co-expressed in 293T or CHO-K1 cells, a furin-like protease activity in these cells cleaved the precursor and produced an active and processed soluble GlcNAc-phosphotransferase with an ␣ 2 ␤ 2 ␥ 2 -subunits arrangement. Recombinant soluble GlcNAc-phosphotransferase exhibited specific activity and substrate preferences similar to the wild type bovine GlcNAcphosphotransferase and was able to phosphorylate a lysosomal hydrolase, acid ␣-glucosidase in vitro.
EXPERIMENTAL PROCEDURES
Expression Vector with a Signal Peptide and Epitope Tag-A double strand nucleotide sequence containing an NheI half-site, Kozak sequence (11), mouse immunoglobulin chain signal peptide and cleavage site (METDTLLLWVLLLWVPGSTGD), HPC4 epitope (EDQVDPRLIDGK) (12) , and a HindIII half-site was constructed by incubating synthetic oligonucleotides. The oligonucleotide sequences that were used are available on request. The annealed double strand nucleotide was inserted between NheI and HindIII sites of pcDNA6/V5/His-A (Invitrogen) and confirmed by sequencing. The resulting vector with signal peptide and epitope tag was cleaved with HindIII and XbaI to insert cDNA encoding partial GlcNAcphosphotransferase ␣/␤-subunits precursor sequences.
Expression Plasmids for Soluble GlcNAc-phosphotransferase ␣/␤-Subunits Precursor, ␣-Subunit, and ␤-Subunit-Soluble GlcNAc-phosphotransferase ␣/␤-subunits precursor was generated by replacing the putative signal anchor/transmembrane domain at the amino terminus (amino acids 1-44) by a signal peptide and epitope tag and truncating the putative carboxyl terminus transmembrane domain (amino acids 1210 -1256) in the wild type sequence (GenBank TM AY687932). The cDNA for the soluble precursor was generated by PCR and inserted between HindIII and XbaI site of the expression vector with a signal peptide and epitope tag. A cDNA for the soluble ␣-subunit was generated by the same method as the precursor except that the whole ␤-subunit was truncated. cDNA for the soluble ␤-subunit was generated by the same method except that the whole ␣-subunit and the first amino acid of the ␤-subunit (amino acid 929) were removed. The detailed methods for generation of these expression plasmids are available on request.
Introduction of Protease Cleavage Sites at the Carboxyl Terminus of the ␣-Subunit-cDNAs encoding the precursor in which 4 -6 amino acid at the carboxyl terminus of the ␣-subunit were changed to satisfy consensus protease cleavage sequences. The consensus sequences used are DDDDK for enterokinase (EC 3.4.21.9), IEGR for factor Xa protease (EC 3.4.21.6), RARYKR for furin (EC 3.4.21.75), and PGAAHY for Genease TM I (variant of subtilisin, EC 3.4.21.62). The detailed methods for generation of these expression plasmids are available on request.
Bicistronic Expression Plasmid for Soluble ␣/␤-Subunits Precursor and ␥-Subunit-An expression plasmid encoding both the soluble ␣/␤-subunits precursor with a furin cleavage site and the wild type ␥-subunit was made using pEE6.1 and pEE14.1 (Lonza Biologics, Allendale, NJ). The cDNA for the soluble ␣/␤-subunits precursor was subcloned into the XbaI site of pEE6.1, and the orientation was checked by sequencing. The ␥-subunit cDNA was subcloned between the HindIII and EcoRI sites of pEE14.1. Then both plasmids were cleaved with NotI and SalI. The NotI-SalI fragment containing the CMV promoter and the soluble ␣/␤-subunits precursor cDNA was inserted between the NotI and SalI sites of the ␥-subunit plasmid in pEE14.1. The resulting plasmid has a CMV promoter upstream of each cDNA.
Transient Expression of GlcNAc-phosphotransferase in 293T Cells-293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine and 10% fetal bovine serum at 37°C in the atmosphere of 5% CO 2 , 95% air. Cells were transfected with a plasmid or a mixture of plasmids using FuGENE 6 (Roche Applied Science). Conditioned medium was harvested 72 h after transfection and analyzed for enzyme activity and protein expression by Western blotting using HPC4 antibody.
Generation of Stable Cell Lines-CHO-K1 cells stably expressing recombinant soluble GlcNAc-phosphotransferase or GAA were developed using the glutamine synthetase gene expression system (Lonza Biologics). Briefly, CHO-K1 cells were transfected with the expression plasmids and selected in the presence of 25 M L-methionine sulfoximine (Sigma). Following screening for enzyme activity to identify transfected cells, the inserted gene was further amplified by selection in 100 -500 M L-methionine sulfoximine. The clones with the highest protein expression level were chosen for protein production. Cell lines for GlcNAc-phosphotransferase and GAA were obtained by the selection with 500 and 100 M L-methionine sulfoximine, respectively, and maintained with the presence of the same concentration of L-methionine sulfoximine.
The CHO-K1 cells expressing GAA were further screened to obtain the cells lacking GlcNAc-transferase I activity using ricin (13) . Ricin (EY Laboratories, San Mateo, CA) was exhaustively dialyzed against potassium phosphate buffer. For selection, 10 7 cells in 10 ml of Dulbecco's modified Eagle's medium were incubated in the presence of 1.3 mg of ricin for 1 h at 37°C. Cells were then plated into 96-well plates at the density of ϳ5,000 cells/well. Ten colonies were formed after 3 weeks. The absence of GlcNAc-transferase I was confirmed by testing N-glycan structure on GAA by peptide-N-glycanase F (New England Biolabs, Beverly, MA) and endoglycosidase H (New England Biolabs) digestion. Cells lacking GlcNAc-transferase I produced GAA with only high mannose-type glycans that are released by endoglycosidase H, whereas wild type cells produced GAA with both complex and high mannose-type glycans, and some of the glycans are resistant to endoglycosidase H.
Purification of Recombinant Soluble GlcNAc-phosphotransferase-CHO-K1 cell lines stably expressing recombinant soluble GlcNAcphosphotransferase with HPC4 epitope were cultured in 1700 cm 2 roller bottles in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 37°C in a 5% CO 2 , 95% air atmosphere. The conditioned medium was harvested every 3-4 days and subsequently clarified and concentrated ϳ10-fold via a tangential flow filtration system equipped with a 30-kDa cut-off BioMax TM membrane (Millipore, Inc., Billerica, MA) and stored at Ϫ20°C until purification. The GlcNAcphosphotransferase was affinity-purified using a calcium-dependent HPC4-Sepharose column followed by anion-exchange chromatography. HPC4-Sepharose was prepared using NHS-activated-Sepharose (Amersham Biosciences). The concentrated medium was loaded onto the HPC4-Sepharose column equilibrated with 1 M NaCl, 50 mM TrisHCl (pH 7.2), 1 mM CaCl 2 , 15 mM MgCl 2 . Unbound materials were removed by washing first with the same buffer and then with 100 mM NaCl, 50 mM Tris (pH 7.2), 1 mM CaCl 2 , 15 mM MgCl 2 . GlcNAc-phosphotransferase was eluted with 100 mM NaCl, 50 mM Tris-HCl (pH 7.2), 15 mM MgCl 2 , 5 mM EGTA. The fractions containing GlcNAc-phosphotransferase were pooled and further purified on a DEAE-Sepharose column (Amersham Biosciences). The pool was diluted six times with 50 mM Hepes (pH 7.2), 15 mM MgCl 2 and loaded onto a DEAE-Sepharose column, followed by a wash with 20 mM NaCl, 50 mM sodium acetate (pH 6.5), 15 mM MgCl 2 . GlcNAc-phosphotransferase was then eluted with 150 mM NaCl, 50 mM sodium acetate (pH 6.5), 15 mM MgCl 2 and stored in aliquots at Ϫ80°C until use.
Purification of GAA with High Mannose-type Glycans-GAA with high mannose-type glycans were produced from CHO-K1 cells stably expressing GAA and lacking GlcNAc-transferase I activity. The cells were cultured in 1700 cm 2 roller bottles in Dulbecco's modified Eagle's medium containing 2.5 g/ml kifunensine (Industrial Research, Ltd., Wellington, New Zealand), 10% fetal bovine serum at 37°C in a 15% CO 2 , 85% air atmosphere. The increased CO 2 concentration was to maintain the conditioned medium as slightly acidic to keep the GAA secreted in the culture medium active. Kifunensine is a mannosidase inhibitor that blocks Golgi mannosidase activity to maintain high mannose-type glycan on GAA. GAA-containing medium was clarified, con-centrated 4-fold as described above, buffer-exchanged with 2 volumes of 20 mM BisTris, pH 5.5, and filtered again. The material was loaded onto DEAE-Sepharose column equilibrated with 20 mM BisTris, pH 5.5, followed by a wash with 20 mM BisTris, pH 5.5. GAA was eluted with 20 mM BisTris, pH 5.5, containing 150 NaCl. Ammonium sulfate was added to the eluate to 0.8 M and then applied to an Octyl-Sepharose (Amersham Biosciences) column equilibrated with 50 mM sodium acetate, pH 5.5, 0.8 M ammonium sulfate buffer. Unbound materials were washed with 50 mM sodium acetate, pH 5.5, 0.8 M ammonium sulfate buffer and GAA was eluted with 50 mM sodium acetate, pH 5.5 buffer. The eluate was concentrated to final protein concentration of ϳ10 mg/ml by ultrafiltration with a polyethersulfone filter with a 30-kDa molecular weight cut-off. The purified GAA was filtered through a 0.22-micron filter and then stored at Ϫ70°C until further processing.
Amino Terminus Amino Acid Sequencing-Subunits of recombinant human GlcNAc-phosphotransferase were separated by SDS-PAGE (6% polyacrylamide gel) (14) under reducing or non-reducing conditions and transferred to a polyvinylidene difluoride membrane (Amersham Biosciences). Each subunit or a mixture of subunits was subjected to amino terminus microsequencing (15) (performed at the Molecular Biology Resource Facility, University of Oklahoma, Health Sciences Center).
GlcNAc-phosphotransferase Assay-GlcNAc-phosphate transferred to ␣-methylmannoside was determined with [␤-
32 P]UDP-GlcNAc as described previously (16, 17) . One unit of GlcNAc-phosphotransferase activity is defined as 1 pmol of GlcNAc phosphate transferred to ␣-methylmannoside/h in a reaction containing 150 M UDP-GlcNAc and 100 mM ␣-methylmannoside.
Phosphorylation of GAA-GAA was phosphorylated in 50 mM sodium acetate, pH 6.5, 20 mM MnCl 2 , 0.0002% 2-mercaptoethanol, and 300 M [␤-32 P]UDP-GlcNAc at 37°C for 1 h or 20°C for 27 h. Protein was precipitated by adding equal volume of 20% trichloroacetic acid and incubating on ice for 30 min and centrifuging for 10 min. Radioactivity in the pellet was measured by the Cerenkov method.
RESULTS

Generation of Soluble GlcNAc-phosphotransferase-GlcNAc-phospho-
transferase is a membrane-bound enzyme, composed of three different subunits in an ␣ 2 ␤ 2 ␥ 2 arrangement. Hydropathy plots of the sequences predicted that the ␣-and ␤-subunits, but not the ␥-subunit, have membrane-spanning domains (Fig. 1A) (7) . To generate an engineered GlcNAcphosphotransferase suitable for overexpression and process use, it was preferred that the enzyme be secreted and soluble in the absence of detergent. In a first attempt to generate a secreted enzyme, the cDNA sequence was modified, removing the putative membrane-spanning domains in the ␣-and ␤-subunits as described under "Experimental Procedures." The first 44 amino acids of the ␣-subunit were replaced by the 21-amino-acid mouse immunoglobulin light chain signal peptide and cleavage site sequence. The replaced region contains the signal anchor sequence (anchor, amino acids 1-10; putative transmembrane domain, amino acids 11-34) To remove the transmembrane domain in the carboxyl terminus region of the ␤-subunit, a stop codon was introduced into the cDNA at amino acid 1209. This deleted the carboxyl terminus 47 amino acids. To facilitate purification, the 12-amino-acid HPC4 epitope (12) was introduced between the signal peptide and the ␣-subunit (Fig. 1B) .
Transient Expression of Soluble GlcNAc-phosphotransferase Yields Inactive Enzyme-Initial studies to generate soluble GlcNAc-phosphotransferase were performed without co-transfection of the ␥-subunit. Previously we observed that GlcNAc-phosphotransferase was expressed in the cell lysate following the transfection of 293T cells with the ␣/␤-subunits precursor cDNA alone, suggesting that the ␥-subunit is not required for activity on small molecule substrates (7) . Transfection of 293T cells with an expression plasmid encoding soluble ␣/␤-subunits precursor (Fig. 1A) resulted in secretion of protein carrying the HPC4 epitope. Western blotting using the HPC4 antibody revealed that the protein (ϳ176 kDa) is expressed as a single band (ϳ176 kDa) at ϳ1 g/ml based on signal intensity (Fig. 2A) . The GlcNAc-phosphotransferase activity in the conditioned 
medium (409 pmol/ml/h) was 250 times higher than the activity from mock-transfected cells (1.6 pmol/ml/h). However, the apparent specific activity of the enzyme (ϳ409,000 pmol/mg/h) was ϳ30 times less than that of purified bovine GlcNAc-phosphotransferase (12, 200 ,000 pmol/mg/h). This large discrepancy in specific activity suggested that the secreted enzyme was largely inactive.
The Soluble ␣/␤-Subunits Precursor Was Not Processed into Mature ␣-and ␤-Subunits-The molecular mass of the expressed protein (ϳ176 kDa) was slightly larger the bovine ␣-subunit (166 kDa (6)) or the predicted soluble ␣-subunit (ϳ162 kDa, calculated based on amino acid replacements). Expression in 293T cells and truncation of the transmembrane domains might affect either the extent of glycosylation or size of the glycans. Because the ␤-subunit was not epitope-tagged, it was impossible to determine whether the 176-kDa band represents the processed ␣-subunit or unprocessed ␣/␤-subunits precursor. To clarify this issue, a plasmid expressing only the epitope-tagged soluble ␣-subunit (truncation at amino acid 928, Fig.  1C ) was generated and expressed to provide a processed ␣-subunit standard. Western blotting of the medium with HPC4 antibody revealed that the product from the ␣/␤-subunits precursor plasmid is significantly larger than the ␣-subunit standard, suggesting that the ␣/␤-cleavage did not occur (Fig. 2B ). This also demonstrated that the ␣-subunit alone is not active, which is consistent with the genetic data in ML II and ML IIIA patients (17) .
Expression of ER-targeted GlcNAc-phosphotransferase ␣/␤-Subunits
Precursor-Wild type GlcNAc-phosphotransferase resides in the ER and cis-Golgi component. Therefore, processing of the ␣/␤-subunits precursor may require a protease localized in the ER or cis-Golgi. By converting the wild type, membrane-bound enzyme into a soluble form, the ER retention time and protease exposure might be reduced. Additionally, overexpression could have exceeded the capacity of the putative ER protease(s). Because the unprocessed enzyme appears to be ϳ30-fold less active than the processed wild type enzyme, we thought any correction of the processing would result in an obvious increase in secreted activity. Therefore, only secreted enzyme activity was monitored in these experiments. To increase the retention time in the ER, the common ER retention signal (KDEL) (18) was added at the carboxyl terminus of the soluble ␣/␤-subunits precursor (Fig. 1D) . This approach did not increase the activity secreted in the medium (not shown).
To increase ER retention time and avoid potential misfolding of the newly synthesized GlcNAc-phosphotransferase, we expressed the soluble ␣/␤-subunits precursor at 20°C, instead of 37°C. However, expression at 20°C did not increase the activity in the medium (not shown).
Expression of Individual ␣-and ␤-Subunits-Because the attempts to improve processing by increasing ER retention time or improving protein folding were unsuccessful, we reasoned it might be possible to assemble an active processed enzyme by co-expression of individual subunits. The soluble ␣-subunit construct was previously described (Fig. 1C) . To generate a soluble ␤-subunit construct, the light chain signal peptide and HPC4 epitope were appended to Thr 930 (Fig. 1E ). Co-expression of soluble ␤-subunit along with the soluble ␣-subunit minimally increased the activity (ϳ200 pmol/ml/h). However, the expression of the ␤-subunit was poor when the conditioned medium was examined by Western blotting using HPC4 antibody (not shown). A second approach to express individual ␣-and ␤-subunits was co-expression of two molecules that have only a single membrane-spanning domain at either the amino or carboxyl terminus (Fig. 1, F and G) . We reasoned that these molecules might be better retained in ER or cisGolgi and therefore processed more effectively. Upon processing, the precursor with the amino terminus membrane-spanning domain (Fig. 1F ) might be processed into a membrane-bound ␣-subunit and soluble ␤-subunit. The precursor with the carboxyl terminus membrane-spanning domain (Fig. 1G ) might be processed into a soluble ␣-subunit and membrane-bound ␤-subunit. The soluble ␣-and ␤-subunits thus produced might form an active soluble GlcNAc-phosphotransferase. Again, this approach did not increase the activity in medium (not shown)
Modification of the ␣/␤-Subunit Junction by Addition of Proteolytic Cleavage Sites-After the failed attempts to express soluble ␣-and ␤-subunits as an active enzyme, we attempted to process the secreted ␣/␤-subunits precursor in vitro. The amino terminus of the ␤-subunit (Asp 929 ) was determined by sequencing the ␤-subunit in the mature, native bovine GlcNAc-phosphotransferase. Although the carboxyl terminus of the processed bovine ␣-subunit is not precisely known, it must be close to amino acid 928 in the precursor according to the molecular mass the ␣-subunit. Therefore, the sequence of the ␣/␤-subunits precursor near amino acid 930 was examined for potential cleavage sequences of described proteases using MacVector TM 7.2 (Accerelys). However, no protease recognition sites were found in this region. Because the native processing protease(s) could not be identified, we introduced cleavage sites for commercially available proteases (enterokinase, factor Xa, furin, or Genease I) at the ␣/␤-subunit junction by replacing the ␣-subunit carboxyl terminus sequence (Figs. 1H and 3A) . When the expression plasmids for these modified soluble ␣/␤-subunits precursors were transfected to 293T cells, sequences containing enterokinase, factor Xa, or Genease I cleavage sites exhibited similar or lower activity than the soluble ␣/␤-subunits precursor with the native cleavage site (Fig. 3A) . In contrast, the sequence containing the furin cleavage site exhibited 11 times higher activity than the soluble ␣/␤-subunits precursor with the native cleavage site (Fig. 3B, upper panel) . To determine whether the increased activity from the furin site construct was because of the processing, Western blotting was performed. As shown in Fig. 3C , the protein expressed from the furin-containing sequence had a molecular mass similar to the ␣-subunit standard, whereas the other expressed proteins were similar in size to the unprocessed ␣/␤-subunits precursor. The furin site-containing construct was expressed less well than others, suggesting that the higher activity observed was because of processing. We concluded that a furin-like protease(s) within the 293T cells processed and activated the soluble ␣/␤-subunits precursor.
To prepare GlcNAc-phosphotransferase with the ␥-subunit, these cleavage site-modified plasmids were co-transfected with the ␥-subunit plasmid. Again, the sequence containing the furin cleavage site resulted in higher activity than other sequences. However, the co-transfection with the ␥-subunit resulted in ϳ6 times lower activity for all the combinations (Fig. 3B, lower panel) . This was due in part to the lower amount of the soluble ␣/␤-subunits precursor plasmid used for the co-transfection. The ␥-subunit appears to regulate the function of GlcNAc-phosphotransferase by restricting non-lysosomal hydrolase substrates (9) . This regulatory role seems to reduce GlcNAc-phosphotransferase activity as previously observed when the full-length ␣/␤-subunits precursor was expressed in 293T cells in the presence and absence of the ␥-subunit (7).
Structure of Recombinant Soluble GlcNAc-phosphotransferase-A CHO-K1 cell line stably expressing the recombinant soluble GlcNAcphosphotransferase was generated as described under "Experimental Procedures." The expression plasmid contains two expression cassettes each with a CMV promoter; one for the modified soluble ␣/␤-subunits precursor (Fig. 1H) and the other for the full-length ␥-subunit. The recombinant soluble GlcNAc-phosphotransferase was purified by affinity chromatography over immobilized HPC4 resin. Although only the ␣-subunit was HPC4-tagged, all the three subunits were detected in the isolated enzyme by SDS-PAGE (Fig. 4A) . SDS-PAGE of the purified material under reducing and non-reducing conditions revealed that the ␣-and ␥-subunits formed disulfide-linked homodimers like the native bovine GlcNAc-phosphotransferase. The ␤-subunit was not disulfidelinked, again, like the native bovine GlcNAc-phosphotransferase (Fig.  4A) . Quantitative amino terminus sequencing of the whole protein revealed that these subunits are present at an ϳ2.2:2:1 molar ratio. The slightly higher content of the ␣-subunit than the ␤-subunit might be because of the presence of the unprocessed ␣/␤-subunits precursor. The lower content of the ␥-subunit suggested that a portion of the purified enzyme does not contain the ␥-subunit.
Amino terminus sequencing showed that the ␣-subunit begins at Asp 21 in the signal peptide, leaving an intact HPC4 epitope on the protein. The ␤-and ␥-subunits contained the amino terminus sequence identical to the predicted sequence (Fig. 4B) . Therefore, the subunit structure of the recombinant soluble GlcNAc-phosphotransferase was ␣Ј 2 ␤Ј 2 ␥ 2, similar to the native bovine GlcNAc-phosphotransferase previously described (Bao et al. (6) ), whereas a portion might be ␣Ј 2 ␤Ј 2 lacking the regulatory ␥-subunit.
Activity of Recombinant Soluble GlcNAc-phosphotransferase-The activity of the processed recombinant soluble GlcNAc-phosphotransferase (␣Ј 2 ␤Ј 2 ␥ 2 ) was compared with native bovine GlcNAc-phosphotransferase. Both preparations transferred ϳ10 7 pmol of GlcNAc-phosphate to ␣-methylmannoside/mg/h, suggesting that transmembrane domains were not required for efficient transfer of GlcNAc-phosphate to low molecular weight acceptors. Further characterization of the enzymatic properties of the soluble recombinant enzyme showed the specificity for the ␣-anomeric form of the acceptor is retained (Fig. 5A) . Additionally the linkage preferences for small molecule substrates were examined. As shown in Fig. 5B , the enzyme transfers GlcNAc-phosphate to the mannose dimer more efficiently when the linkage is
On the high mannose-type glycans on lysosomal enzymes, phosphorylation is mainly observed on the mannose in ␣-1,2-linkage (19) . Therefore, we concluded that the recombinant soluble GlcNAc-phosphotransferase maintained the same substrate preference as native GlcNAc-phosphotransferase.
Phosphorylation of the Lysosomal Enzyme; Acid ␣-Glucosidase-To investigate substrate specificity with a lysosomal enzyme substrate, acid ␣-glucosidase (GAA) was chosen. GAA expressed with high mannose-type glycans was phosphorylated using the purified recombinant soluble GlcNAc-phosphotransferase and [
32 P]UDP-GlcNAc at 37°C for 1 h. The amount of the GlcNAc-phosphate incorporated into GAA is shown in Fig. 6A . The K m for GAA was calculated to be ϳ12 M. It is similar to the K m determined for bovine GlcNAcphosphotransferase using uteroferrin (22 M) or cathepsin D (16 M) as acceptor (10) . However, the V max of recombinant GlcNAcphosphotransferase on GAA was 31 ϫ 10 3 pmol/mg/h, which is ϳ140 times lower than bovine enzyme on uteroferrin (10). The same reaction was performed at 20°C for a longer time (27 h) to ensure that phosphorylation can be performed at lower temperature where both GlcNAc-phosphotransferase and GAA are more stable (Fig.  6B) . GAA was phosphorylated with similar K m (23 M) and even lower V max (11 ϫ 10 3 pmol/mg/h) at 20°C. Interestingly, phosphorylation of the recombinant phosphotransferase itself was observed in the absence of GAA substrate (data not shown). The amount of GlcNAc-phosphate transferred to GAA was determined by subtracting the amount transferred in the absence of GAA. We concluded that the recombinant soluble GlcNAc-phosphotransferase retained the ability to phosphorylate a lysosomal hydrolase substrate in vitro.
DISCUSSION
We have successfully generated a recombinant soluble GlcNAcphosphotransferase by molecular engineering of the human GlcNAcphosphotransferase ␣/␤-subunits precursor cDNA. To generate this molecule, transmembrane domains on the ␣-and ␤-subunits were removed, and a furin cleavage site was introduced between the ␣-and ␤-subunits, whereas no modification was made to the ␥-subunit cDNA. The recombinant soluble GlcNAc-phosphotransferase was expressed in mammalian cells and secreted in medium as an ␣Ј 2 ␤Ј 2 ␥ 2 configuration 
